Telix Pharmaceuticals (ASX:TLX) announced the launch of a US$550 million offering of senior unsecured convertible notes due 2031.
The capital raise serves as a proactive refinancing vehicle for the company's existing convertible bonds maturing in 2029.
The new notes, guaranteed by Telix's parent entity and its US subsidiary, are slated for listing on the Singapore Exchange.
Investors can expect a coupon rate between 1.50% and 1.75%, featuring a conversion premium of 35.0% to 37.5% over the current share price.
The structure provides the oncology specialist with high-flexibility, low-cost capital that remains non-dilutive to shareholders until any potential future conversion events.
Managing Director and Group CEO Dr. Christian Behrenbruch emphasised that the transaction reflects a disciplined approach to capital management, ensuring the business maintains a robust financial runway to support its global commercialisation efforts.
J.P. Morgan is acting as the sole bookrunner for the offering and as the sole dealer manager for the concurrent repurchase of the 2029 bonds.
The final bookbuild is expected to conclude before the Australian market opens on April 15.